{"id":"https://openalex.org/W7207665293","doi":"https://doi.org/10.3390/curroncol33090536","title":"Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review","display_name":"Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review","publication_year":2026,"publication_date":"2026-09-03","ids":{"openalex":"https://openalex.org/W7207665293","doi":"https://doi.org/10.3390/curroncol33090536","pmid":"https://pubmed.ncbi.nlm.nih.gov/42782882","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13605042"},"language":"en","primary_location":{"id":"doi:10.3390/curroncol33090536","doi":"https://doi.org/10.3390/curroncol33090536","is_oa":true,"landing_page_url":"https://doi.org/10.3390/curroncol33090536","pdf_url":null,"source":{"id":"https://openalex.org/S113449754","display_name":"Current Oncology","issn_l":"1198-0052","issn":["1198-0052","1718-7729"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3390/curroncol33090536","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5128896703","display_name":"Marclesson  Santos Alves","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marclesson Santos Alves","raw_affiliation_strings":["Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119865346","display_name":"Juliana Pal\u00e1cio de Queiroz Ventura Barros","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Juliana Pal\u00e1cio de Queiroz Ventura Barros","raw_affiliation_strings":["Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112125824","display_name":"Danielle Calheiros Campelo Maia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Calheiros Campelo Maia","raw_affiliation_strings":["Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031088021","display_name":"Igor Santos Costa","orcid":"https://orcid.org/0000-0002-0127-3698","observed_orcids":["https://orcid.org/0000-0002-0127-3698"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Santos Costa","raw_affiliation_strings":["Argos Patologia, Fortaleza 60175-047, CE, Brazil"],"raw_orcid":"https://orcid.org/0000-0002-0127-3698","affiliations":[{"raw_affiliation_string":"Argos Patologia, Fortaleza 60175-047, CE, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106995653","display_name":"Ormando Rodrigues Campos J\u00fanior","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ormando Rodrigues Campos Junior","raw_affiliation_strings":["Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045500016","display_name":"Howard Lopes Ribeiro","orcid":"https://orcid.org/0000-0003-2431-4779","observed_orcids":["https://orcid.org/0000-0003-2431-4779"]},"institutions":[{"id":"https://openalex.org/I243754102","display_name":"Universidade Federal do Cear\u00e1","ror":"https://ror.org/03srtnf24","country_code":"BR","type":"education","lineage":["https://openalex.org/I243754102"]}],"countries":["BR"],"is_corresponding":true,"raw_author_name":"Howard Lopes Ribeiro Junior","raw_affiliation_strings":["Post-Graduate Program in Pathology, Post-Graduate Program in Translational Medicine, Center for Research and Drug Development (NPDM), Federal University of Cear\u00e1, Fortaleza 60430-275, CE, Brazil"],"raw_orcid":"https://orcid.org/0000-0003-2431-4779","affiliations":[{"raw_affiliation_string":"Post-Graduate Program in Pathology, Post-Graduate Program in Translational Medicine, Center for Research and Drug Development (NPDM), Federal University of Cear\u00e1, Fortaleza 60430-275, CE, Brazil","institution_ids":["https://openalex.org/I243754102"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045500016"],"corresponding_institution_ids":["https://openalex.org/I243754102"],"apc_list":{"value":2200,"currency":"CHF","value_usd":2654},"apc_paid":{"value":2200,"currency":"CHF","value_usd":2654},"fwci":5.3579,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.96119611,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"33","issue":"9","first_page":"536","last_page":"536"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.8604000210762024,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.8604000210762024,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.13109999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/cutaneous-hyperpigmentation","display_name":"cutaneous hyperpigmentation","score":0.9829999804496765},{"id":"https://openalex.org/keywords/egfr-l858r-mutation","display_name":"L858R mutation","score":0.9509999752044678},{"id":"https://openalex.org/keywords/non-small-cell-lung-adenocarcinoma","display_name":"non-small cell lung adenocarcinoma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/adjuvant-targeted-therapy","display_name":"adjuvant targeted therapy","score":0.8159999847412109},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.8199999928474426},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.7020000219345093},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.5540000200271606},{"id":"https://openalex.org/keywords/lobectomy","display_name":"lobectomy","score":0.5820000171661377},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.6389999985694885},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.8360000252723694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9550999999046326},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9247999787330627},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6243000030517578},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6176999807357788},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.5830000042915344},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5468000173568726},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.48010000586509705},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4672999978065491},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.46700000762939453},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.43459999561309814},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43220001459121704},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.42410001158714294},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.4228000044822693},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.3846000134944916},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38350000977516174},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.36719998717308044},{"id":"https://openalex.org/C2780849966","wikidata":"https://www.wikidata.org/wiki/Q170758","display_name":"Lymph node","level":2,"score":0.3610999882221222},{"id":"https://openalex.org/C2778168870","wikidata":"https://www.wikidata.org/wiki/Q6725808","display_name":"Maculopapular rash","level":3,"score":0.3528999984264374},{"id":"https://openalex.org/C207886595","wikidata":"https://www.wikidata.org/wiki/Q1456138","display_name":"Pathological","level":2,"score":0.34860000014305115},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3353999853134155},{"id":"https://openalex.org/C2779563347","wikidata":"https://www.wikidata.org/wiki/Q843799","display_name":"Adenocarcinoma of the lung","level":4,"score":0.30959999561309814},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.30649998784065247},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.3052000105381012},{"id":"https://openalex.org/C2776728111","wikidata":"https://www.wikidata.org/wiki/Q1641068","display_name":"Hyperpigmentation","level":2,"score":0.3005000054836273},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.2881999909877777},{"id":"https://openalex.org/C2780379385","wikidata":"https://www.wikidata.org/wiki/Q1916209","display_name":"Mediastinal lymph node","level":4,"score":0.27970001101493835},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.25859999656677246},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.25690001249313354},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2567000091075897}],"mesh":[{"descriptor_ui":"D000077192","descriptor_name":"Adenocarcinoma of Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000077192","descriptor_name":"Adenocarcinoma of Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D000077192","descriptor_name":"Adenocarcinoma of Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017495","descriptor_name":"Hyperpigmentation","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.3390/curroncol33090536","doi":"https://doi.org/10.3390/curroncol33090536","is_oa":true,"landing_page_url":"https://doi.org/10.3390/curroncol33090536","pdf_url":null,"source":{"id":"https://openalex.org/S113449754","display_name":"Current Oncology","issn_l":"1198-0052","issn":["1198-0052","1718-7729"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Oncology","raw_type":"journal-article"},{"id":"pmid:42782882","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42782882","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current oncology (Toronto, Ont.)","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13605042","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13605042/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Curr Oncol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:65a6a7859e06480aabb5f54394defdd1","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/65a6a7859e06480aabb5f54394defdd1","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current Oncology, Vol 33, Iss 9, p 536 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3390/curroncol33090536","doi":"https://doi.org/10.3390/curroncol33090536","is_oa":true,"landing_page_url":"https://doi.org/10.3390/curroncol33090536","pdf_url":null,"source":{"id":"https://openalex.org/S113449754","display_name":"Current Oncology","issn_l":"1198-0052","issn":["1198-0052","1718-7729"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[{"id":"https://openalex.org/G1982144742","display_name":null,"funder_award_id":"305659/2023-5","funder_id":"https://openalex.org/F4320322025","funder_display_name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico"},{"id":"https://openalex.org/G322104931","display_name":null,"funder_award_id":"444227/2025\u20103","funder_id":"https://openalex.org/F4320322025","funder_display_name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico"},{"id":"https://openalex.org/G7946038776","display_name":null,"funder_award_id":"408566/2024\u20108","funder_id":"https://openalex.org/F4320322025","funder_display_name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico"}],"funders":[{"id":"https://openalex.org/F4320322025","display_name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","ror":"https://ror.org/03swz6y49"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W2546505767","https://openalex.org/W2591118779","https://openalex.org/W2770828094","https://openalex.org/W2797760005","https://openalex.org/W2885865369","https://openalex.org/W2921836804","https://openalex.org/W2990041408","https://openalex.org/W2999656522","https://openalex.org/W3010280371","https://openalex.org/W3037626323","https://openalex.org/W3048473072","https://openalex.org/W3087210493","https://openalex.org/W3087614196","https://openalex.org/W4220901918","https://openalex.org/W4283310759","https://openalex.org/W4311677159","https://openalex.org/W4318486258","https://openalex.org/W4379280261","https://openalex.org/W4391745477","https://openalex.org/W4405312321","https://openalex.org/W4406778058","https://openalex.org/W4408015012","https://openalex.org/W4408501974","https://openalex.org/W4411302254","https://openalex.org/W4413714143","https://openalex.org/W4413889144","https://openalex.org/W7155184118"],"related_works":["https://openalex.org/W4220901918","https://openalex.org/W4412755087","https://openalex.org/W2999656522","https://openalex.org/W7133552472","https://openalex.org/W7128910472","https://openalex.org/W4405312321","https://openalex.org/W4402082292","https://openalex.org/W4415519745","https://openalex.org/W4414631774","https://openalex.org/W4224944657"],"abstract_inverted_index":{"The":[0],"use":[1],"of":[2,68,140,164,182],"targeted":[3],"therapies":[4],"has":[5],"improved":[6],"outcomes":[7],"in":[8,103],"patients":[9],"with":[10,34,143,158],"resected":[11,35],"epidermal":[12,40],"growth":[13,41],"factor":[14,42],"receptor-mutated":[15],"non-small":[16],"cell":[17],"lung":[18,36],"cancer,":[19],"but":[20],"uncommon":[21,152],"and":[22,52,97,122,129,153,160,173,179],"persistent":[23,85],"dermatologic":[24,98,155,177],"toxicities":[25],"remain":[26],"poorly":[27],"characterized.":[28],"We":[29],"report":[30],"a":[31,84],"71-year-old":[32],"woman":[33],"adenocarcinoma":[37],"harboring":[38],"an":[39,151],"receptor":[43],"exon":[44],"21":[45],"L858R":[46],"mutation.":[47],"Following":[48],"right":[49],"upper":[50],"lobectomy":[51],"systematic":[53],"mediastinal":[54],"lymph":[55],"node":[56],"dissection,":[57],"pathological":[58],"staging":[59],"was":[60,94,100,126],"pT2aN1M0":[61],"(stage":[62],"IIB).":[63],"She":[64],"received":[65],"four":[66],"cycles":[67],"adjuvant":[69,77],"cisplatin":[70],"plus":[71],"pemetrexed":[72],"followed":[73],"by":[74,89],"planned":[75],"three-year":[76],"Osimertinib.":[78],"During":[79],"Osimertinib":[80,93,125,159],"treatment,":[81],"she":[82],"developed":[83],"violaceous":[86],"rash":[87],"accompanied":[88],"progressive":[90],"cutaneous":[91,167],"hyperpigmentation.":[92],"temporarily":[95],"interrupted,":[96],"evaluation":[99,178],"performed,":[101],"resulting":[102],"partial":[104],"clinical":[105],"improvement.":[106],"Hyperpigmentation,":[107],"however,":[108],"persisted":[109],"during":[110],"follow-up.":[111],"Other":[112],"adverse":[113],"events":[114],"included":[115],"grade":[116],"1":[117],"diarrhea,":[118],"transient":[119],"arthralgia,":[120],"anorexia,":[121],"weight":[123],"loss.":[124],"subsequently":[127],"resumed":[128],"maintained.":[130],"Nearly":[131],"two":[132],"years":[133],"after":[134],"surgery,":[135],"the":[136,162],"patient":[137],"remains":[138],"free":[139],"disease":[141],"recurrence,":[142],"stable":[144],"pigmentary":[145],"skin":[146],"changes.":[147],"This":[148],"case":[149],"highlights":[150],"prolonged":[154],"manifestation":[156],"associated":[157],"emphasizes":[161],"importance":[163],"recognizing":[165],"atypical":[166],"toxicity":[168],"to":[169,174],"facilitate":[170,175],"appropriate":[171,176],"management":[172,181],"individualized":[180],"treatment-related":[183],"toxicity.":[184]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-09-04T00:00:00"}